Coinfecția TB/COVID-19: ce avem?

Rezumat

Aim. Assessment of the impact of COVID-19 on the clinical course of tuberculosis in patients hospitalized at the Research Institute of Lung Diseases in Baku.103 patients with TB/COVİD-19 co-infection aged 21-74 years were examined. In patients with TB/COVİD-19 co-infection, the duration of TB disease was up to 1 month in 13.8%, from 1 to 6 months in 4.6%, and more than 6 months in 81.6% of patients. The duration of COVID-19 disease was up to 1 week in 35.6%, more than 1 week in 64.4% of patients. Contamination with two different infections affecting the lung tissue has contributed to frequent inaccuracies in a radiological examination of patients with TB/COVID-19 co-infection. The majority of patients (79.6%) were diagnosed with pulmonary TB, with 54.2% of them having a bilateral process. Extrapulmonary TB was diagnosed in 7.8% of patients. Viral pneumonia due to COVID-19 was observed in 78.6% of patients. Clinical symptoms of patients with TB/ COVİD-19 co-infection are characterized by an abundance of complaints from the same patient. Cases of resistant forms of tuberculosis among these patients amounted to 16.5%, which is higher than the rate for resistant TB in the country. Of these, 9 resistance to anti-tuberculosis drugs was detected for the first time. Secondary respiratory flora was found in 42.7% of patients with TB/COVİD-19 co-infection. Among patients with TB/COVİD-19 co-infection, death was observed in 9.7% of cases, which is much higher than the mortality rates from TB and COVID-19 in the country.